Today's Daily Dose brings you news about Alnylam's promising preliminary phase I trial results of investigational Lumasiran for the treatment of Primary Hyperoxaluria Type 1; an update on Anavex Life's ANAVEX2-73 trial results in mild-to-moderate Alzheimer's patients and Dynavax's upcoming regulatory catalyst.
from RTT - Biotech http://ift.tt/2yyiJgg
via IFTTT
No comments:
Post a Comment